首页> 外文期刊>Nature Communications >Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug
【24h】

Tumour-associated macrophages act as a slow-release reservoir of nano-therapeutic Pt(IV) pro-drug

机译:肿瘤相关巨噬细胞充当纳米治疗Pt(IV)前药的缓释储库

获取原文
       

摘要

Therapeutic nanoparticles (TNPs) aim to deliver drugs more safely and effectively to cancers, yet clinical results have been unpredictable owing to limited in vivo understanding. Here we use single-cell imaging of intratumoral TNP pharmacokinetics and pharmacodynamics to better comprehend their heterogeneous behaviour. Model TNPs comprising a fluorescent platinum(IV) pro-drug and a clinically tested polymer platform (PLGA- b -PEG) promote long drug circulation and alter accumulation by directing cellular uptake toward tumour-associated macrophages (TAMs). Simultaneous imaging of TNP vehicle, its drug payload and single-cell DNA damage response reveals that TAMs serve as a local drug depot that accumulates significant vehicle from which DNA-damaging Pt payload gradually releases to neighbouring tumour cells. Correspondingly, TAM depletion reduces intratumoral TNP accumulation and efficacy. Thus, nanotherapeutics co-opt TAMs for drug delivery, which has implications for TNP design and for selecting patients into trials.
机译:治疗性纳米粒子(TNP)旨在更安全有效地将药物递送给癌症,但由于对体内的了解有限,因此临床结果无法预测。在这里,我们使用肿瘤内TNP药代动力学和药效学的单细胞成像,以更好地理解其异质性行为。包含荧光铂(IV)前药和经过临床测试的聚合物平台(PLGA-b -PEG)的模型TNP通过引导细胞向肿瘤相关的巨噬细胞(TAM)摄取,促进了较长的药物循环并改变了累积。对TNP载体,其药物有效载荷和单细胞DNA损伤反应的同时成像显示,TAM充当了一个局部药物仓库,积累了重要的载体,破坏DNA的Pt有效载荷逐渐从该载体释放到邻近的肿瘤细胞中。相应地,TAM消耗减少了肿瘤内TNP的积累和功效。因此,纳米治疗药物选择了TAM来进行药物输送,这对TNP设计和选择患者进行试验具有重要意义。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号